These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32986499)

  • 21. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.
    Tomar DS; Li L; Broulidakis MP; Luksha NG; Burns CT; Singh SK; Kumar S
    MAbs; 2017 Apr; 9(3):476-489. PubMed ID: 28125318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biophysical properties of the clinical-stage antibody landscape.
    Jain T; Sun T; Durand S; Hall A; Houston NR; Nett JH; Sharkey B; Bobrowicz B; Caffry I; Yu Y; Cao Y; Lynaugh H; Brown M; Baruah H; Gray LT; Krauland EM; Xu Y; Vásquez M; Wittrup KD
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):944-949. PubMed ID: 28096333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.
    Alam ME; Barnett GV; Slaney TR; Starr CG; Das TK; Tessier PM
    Mol Pharm; 2019 May; 16(5):1939-1949. PubMed ID: 30916563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.
    Tessier PM; Wu J; Dickinson CD
    Expert Opin Drug Deliv; 2014 Apr; 11(4):461-5. PubMed ID: 24444112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of automated Wes system as an analytical and characterization tool to support monoclonal antibody drug product development.
    Wang J; Valdez A; Chen Y
    J Pharm Biomed Anal; 2017 May; 139():263-268. PubMed ID: 28069351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.
    Gupta P; Makowski EK; Kumar S; Zhang Y; Scheer JM; Tessier PM
    Mol Pharm; 2022 Mar; 19(3):775-787. PubMed ID: 35108018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
    Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
    J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of monoclonal antibody viscosity using interpretable machine learning.
    Makowski EK; Chen HT; Wang T; Wu L; Huang J; Mock M; Underhill P; Pelegri-O'Day E; Maglalang E; Winters D; Tessier PM
    MAbs; 2024; 16(1):2303781. PubMed ID: 38475982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of interpretable artificial neural networks to early monoclonal antibodies development.
    Gentiluomo L; Roessner D; Augustijn D; Svilenov H; Kulakova A; Mahapatra S; Winter G; Streicher W; Rinnan Å; Peters GHJ; Harris P; Frieß W
    Eur J Pharm Biopharm; 2019 Aug; 141():81-89. PubMed ID: 31112768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.
    Kayser V; Chennamsetty N; Voynov V; Forrer K; Helk B; Trout BL
    Biotechnol J; 2011 Jan; 6(1):38-44. PubMed ID: 20949542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers.
    Heads JT; Kelm S; Tyson K; Lawson ADG
    MAbs; 2022; 14(1):2138092. PubMed ID: 36418193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Streamlining the polishing step development process via physicochemical characterization of monoclonal antibody aggregates.
    Doss HR; Raman M; Knihtila R; Chennamsetty N; Wang D; Shupe A; Mussa N
    J Chromatogr A; 2019 Aug; 1598():101-112. PubMed ID: 30954243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of a platform process operating space for a monoclonal antibody susceptible to reversible and irreversible aggregation using a solution stability screening approach.
    Man A; Luo H; Levitskaya SV; Macapagal N; Newell KJ
    J Chromatogr A; 2019 Jul; 1597():100-108. PubMed ID: 30922716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of IgG isotypes in serum.
    Correia IR
    MAbs; 2010; 2(3):221-32. PubMed ID: 20404539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.
    Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C
    Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Russell body phenotype is preferentially induced by IgG mAb clones with high intrinsic condensation propensity: relations between the biosynthetic events in the ER and solution behaviors in vitro.
    Hasegawa H; Woods CE; Kinderman F; He F; Lim AC
    MAbs; 2014; 6(6):1518-32. PubMed ID: 25484054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.